Cargando…
Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy
The efficacy of tamsulosin at the cost of a relatively benign side effect profile has been attributed to receptor selectivity directed at the α(1a) and α(1d) adrenergic receptor subtypes. The oral-controlled absorption system (OCAS(®)) represents a drug delivery refinement that incorporates a matrix...
Autores principales: | Neill, Mischel G, Shahani, Rohan, Zlotta, Alexandre R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503646/ https://www.ncbi.nlm.nih.gov/pubmed/18728700 |
Ejemplares similares
-
An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin
por: Yang, Pei-Shan, et al.
Publicado: (2018) -
Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014) -
Non-Invasive Predictors of Response to Tamsulosin for Benign Prostatic Obstruction
por: Shoaib, Mohammad, et al.
Publicado: (2021) -
Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019) -
Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)